Steven W. King - 03 Sep 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Reporting relationship: Director
Issuer ticker: OTLC
Reported as of: 03 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Sep 2021, 17:00:44 UTC
Prior SEC filing: 16 Jul 2021
Next SEC filing: 22 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Steven W. King

Key filing fact

Steven W. King filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 08 Sep 2021.

Key facts

This page summarizes Steven W. King's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Sep 2021, 17:00.

Change

Previous filing in this sequence was filed on 16 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLC transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 03 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.1393
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022.